Tirzepatide Peptide – Dual GIP/GLP-1 Agonist | 99% Ultra-Pure for Fat Loss, Insulin Sensitivity & Metabolic Research

Elevate your research with Tirzepatide – a cutting-edge dual incretin receptor agonist that activates both GLP-1 and GIP receptors. This breakthrough compound is reshaping the landscape of obesity, insulin resistance, and type 2 diabetes studies.

Now available in 99% HPLC-tested purity, Tirzepatide provides exceptional consistency and reliability for metabolic and longevity-based research applications.

Why Choose Our Tirzepatide (99% Purity)?

• Dual Agonist Power
  Combines GLP-1 and GIP receptor activation to deliver enhanced fat loss, appetite control, and insulin sensitivity.

• 99% Purity – Pharmaceutical Grade
  HPLC-tested for maximum integrity, ensuring research-grade quality and dependable lab outcomes.

• Clinically Proven Pathways
  Demonstrated in trials to outperform GLP-1-only peptides in body weight reduction and metabolic improvement.

• Long-Acting Action
  Formulated for prolonged activity, mimicking once-weekly dosing protocols for efficiency in preclinical studies.

Product Specifications

• Purity: ≥99% (HPLC Verified)

• Form: Lyophilized peptide powder in sterile 2mg or 5mg vials

• Storage: Store dry at –20°C. Once reconstituted, refrigerate and use within 7–10 days.

Research Applications

• Weight loss and fat metabolism studies

• Insulin sensitivity and glycemic control models

• Appetite suppression and hormonal regulation

• Preclinical obesity and type 2 diabetes protocols
  

For Research Use Only

This compound is intended for laboratory research purposes only. It is not approved for human consumption, therapeutic use, or diagnostic procedures. Use in accordance with applicable research laws and guidelines.